2020
DOI: 10.1007/s12254-020-00571-7 View full text |Buy / Rent full text
|
|

Abstract: SummaryStarting with the approval of bortezomib, a proteasome-inhibiting drug, tremendous progress has been achieved in the treatment of multiple myeloma (MM) patients during the last 15 years. Due to a plethora of novel drugs such as second generation proteasome inhibitors, immunomodulating agents and monoclonal antibodies the 5‑year survival of MM patients has been extended from 33% at the turn of the millennium to approximately 60% in younger patients (<65–70 years) who were eligible for consolidation wi… Show more

Help me understand this report

Search citation statements

Order By: Relevance
Select...
0
5
0

Publication Types

Select...

Relationship

0
0

Authors

Journals